CONNECTA Therapeutics is taking a new approach to Fragile X syndrome treatment by boosting the brain’s natural ability to reconnect and adapt.
Bowen’s FX Therapeutics, a company with roots in the Fragile X community, is advancing efforts toward a future protein replacement therapy.
On July 27, 2024, at the 19th NFXF International Fragile X Conference, three of our industry partners working on treatments for Fragile X syndrome presented updates on their research.
Healx presents during the 2022 Industry Updates Keynote at the 18th International Fragile X Conference.
A message about Shionogi’s EXPERIENCE clinical trials from Dr. Juan-Carlos Gomez, Chief Medical Officer at Shionogi & Co., Ltd.
On September 19, 2023, the NFXF hosted a Fragile X research update webinar with three of our industry partners working on treatments for Fragile X syndrome.
Allos Pharma announced they held a meeting with the FDA to optimize the design of their Phase 3 trial designed to support an NDA to address FXS.
Chad Coberly, CEO of Tetra Therapeutics, a Shionogi Group Company, presented about BPN14770, a PDE4 inhibitor, during the Industry Updates keynote session at the 18th International Fragile X Conference.
It’s that time of year! Our 2022 Industry Updates session, moderated by Hilary Rosselot, includes presentations from Asuragen, Zynerba Pharmaceuticals, Tetra Therapeutics, and Healx.
On September 14, 2021, we held an NFXF webinar with three of our industry partners working on treatments for Fragile X syndrome. Each shared the most up-to-date information on their research projects in a way more easily understood by laypeople. A short Q&A followed each presentation.
Allos Pharma, a late-stage pharmaceutical company developing therapeutics for neurodevelopmental disorders, has announced the exclusive license rights to arbaclofen in Fragile X syndrome.
